JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB104015

Recombinant Human FAHD1/Oxaloacetate decarboxylase protein

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human FAHD1/Oxaloacetate decarboxylase protein is a Human Full Length protein, in the 1 to 224 aa range, expressed in Escherichia coli, with >95%, suitable for SDS-PAGE, Mass Spec.

View Alternative Names

C16orf36, YISKL, FAHD1, Acylpyruvase FAHD1, Fumarylacetoacetate hydrolase domain-containing protein 1, Oxaloacetate decarboxylase, YisK-like protein, FAH domain-containing protein 1, OAA decarboxylase, ODx

1 Images
SDS-PAGE - Recombinant Human FAHD1/Oxaloacetate decarboxylase protein (AB104015)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human FAHD1/Oxaloacetate decarboxylase protein (AB104015)

3ug by SDS-PAGE under reducing conditions and visualized by coomassie blue stain.

Key facts

Purity

>95% SDS-PAGE

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

SDS-PAGE, Mass Spec

applications

Biologically active

No

Accession

Q6P587

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 10% Glycerol (glycerin, glycerine), 0.58% Sodium chloride, 0.316% Tris HCl, 0.0154% (R*,R*)-1,4-Dimercaptobutan-2,3-diol

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

This product was previously labelled as FAHD1
style
left-column

Sequence info

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMGIMAASRPLSRFWEWGKNIVCVGRNYADHVREMRSAVLSEPVLFLKPSTAYAPEGSPILMPAYTRNLHHELELGVVMGKRCRAVPEAAAMDYVGGYALCLDMTARDVQDECKKKGLPWTLAKSFTASCPVSAFVPKEKIPDPHKLKLWLKVNGELRQEGETSSMIFSIPYIISYVSKIITLEEGDIILTGTPKGVGPVKENDEIEAGIHGLVSMTFKVEKPEY","proteinLength":"Full Length","predictedMolecularWeight":"27 kDa","actualMolecularWeight":null,"aminoAcidEnd":224,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"Q6P587","tags":[{"tag":"His","terminus":"N-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

FAHD1 also known as oxaloacetate decarboxylase is an enzyme that plays an important role in metabolic processes by converting oxaloacetate into pyruvate. This enzyme has a molecular mass of approximately 28 kDa. Researchers have detected FAHD1 expression in organisms across various tissues including humans where it appears in mitochondria. Though studies are ongoing FAHD1 is well-established in terms of its function and significance in cellular metabolism.
Biological function summary

FAHD1 takes part in energy regulation within cells by modulating levels of oxaloacetate and pyruvate. While not part of a larger enzymatic complex FAHD1 interacts with other metabolic enzymes to maintain cellular energy homeostasis. The enzyme's activity affects processes involving energy production showing that its correct functioning is essential for cellular health. Therefore understanding FAHD1's interaction within cells provides insights into its broader role in metabolism.

Pathways

FAHD1 operates primarily within the citric acid cycle sharing pathways with other metabolic enzymes like pyruvate carboxylase. This involvement supports its function in maintaining metabolic balance by influencing levels of intermediates like oxaloacetate. Additionally FAHD1 links with other enzymes in the gluconeogenesis pathway indicating its broader significance in the generation of glucose from non-carbohydrate sources. Such pathways highlight FAHD1's role in both energy production and glucose synthesis.

FAHD1 links closely to conditions such as metabolic syndrome and neurodegenerative diseases. Altered FAHD1 activity can affect cellular metabolism thereby contributing to obesity-related disorders which include insulin resistance and type 2 diabetes. Furthermore FAHD1 alterations might associate with proteins like pyruvate dehydrogenase and affect energy metabolism potentially impacting neurodegenerative conditions such as Alzheimer's disease. This connection indicates that FAHD1 might be a target for therapeutic strategies aiming to manage these diseases.
style
left-column

Specifications

Form

Liquid

Additional notes

Purified by using anion-exchange chromatography (DEAE sepharose resin) and gel-filtration chromatography (Sephacryl S-200) with 20mM Tris pH 7.5, 2mM EDTA.

style
left-column

General info

Function

Tautomerase that converts enol-oxaloacetate, a strong inhibitor of succinate dehydrogenase, to the physiological keto form of oxaloacetate (PubMed : 38287013). It is thereby required to maximize aerobic respiration efficiency by preventing succinate dehydrogenase inhibition (PubMed : 38287013). Also acts as a weak oxaloacetate decarboxylase (ODx), catalyzing the decarboxylation of oxaloacetate (OAA) to pyruvate and CO(2), and as such is likely a regulatory enzyme in the TCA cycle (PubMed : 25575590, PubMed : 30348641). Also displays acylpyruvase activity, being able to hydrolyze acetylpyruvate and fumarylpyruvate in vitro (PubMed : 21878618, PubMed : 30348641). Exhibits only a weak hydrolase activity on methylacetopyruvate and acetylacetone, and no activity toward acetoacetyl-CoA (PubMed : 21878618).

Sequence similarities

Belongs to the FAH family.

Subcellular localisation

Mitochondrion

style
left-column

Product protocols

style
left-column

Target data

Tautomerase that converts enol-oxaloacetate, a strong inhibitor of succinate dehydrogenase, to the physiological keto form of oxaloacetate (PubMed : 38287013). It is thereby required to maximize aerobic respiration efficiency by preventing succinate dehydrogenase inhibition (PubMed : 38287013). Also acts as a weak oxaloacetate decarboxylase (ODx), catalyzing the decarboxylation of oxaloacetate (OAA) to pyruvate and CO(2), and as such is likely a regulatory enzyme in the TCA cycle (PubMed : 25575590, PubMed : 30348641). Also displays acylpyruvase activity, being able to hydrolyze acetylpyruvate and fumarylpyruvate in vitro (PubMed : 21878618, PubMed : 30348641). Exhibits only a weak hydrolase activity on methylacetopyruvate and acetylacetone, and no activity toward acetoacetyl-CoA (PubMed : 21878618).
See full target information FAHD1
style
left-column
style
left-column
style
right-column

Complementary Products

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Secondary Antibodies

AB150121

Goat Anti-Mouse IgM mu chain (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Mouse IgM mu chain (Alexa Fluor® 488) (AB150121)

  • 5
  • 5
Secondary Antibodies

AB99695

Mouse monoclonal [SB62a] Anti-Rabbit IgG light chain

  • 0
  • 0
Secondary Antibodies

AB99811

Mouse monoclonal [JDC-12] Anti-Human lambda light chain (HRP)

VeriBlot

  • 5
  • 1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com